These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

810 related articles for article (PubMed ID: 31511071)

  • 21. Atezolizumab for the treatment of non-small cell lung cancer.
    Santini FC; Rudin CM
    Expert Rev Clin Pharmacol; 2017 Sep; 10(9):935-945. PubMed ID: 28714780
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anlotinib enhanced CD8
    Luo J; Cheng K; Ji X; Gao C; Zhu R; Chen J; Xue W; Huang Q; Xu Q
    Cancer Lett; 2024 Jun; 591():216892. PubMed ID: 38621459
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.
    Redin E; Garmendia I; Lozano T; Serrano D; Senent Y; Redrado M; Villalba M; De Andrea CE; Exposito F; Ajona D; Ortiz-Espinosa S; Remirez A; Bertolo C; Sainz C; Garcia-Pedrero J; Pio R; Lasarte J; Agorreta J; Montuenga LM; Calvo A
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658304
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic.
    Vilariño N; Bruna J; Bosch-Barrera J; Valiente M; Nadal E
    Cancer Treat Rev; 2020 Sep; 89():102067. PubMed ID: 32682248
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-PD-(L)1 immunotherapy for brain metastases in non-small cell lung cancer: Mechanisms, advances, and challenges.
    Zhou S; Xie J; Huang Z; Deng L; Wu L; Yu J; Meng X
    Cancer Lett; 2021 Apr; 502():166-179. PubMed ID: 33450361
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The clinical utility of PD-L1 testing in selecting non-small cell lung cancer patients for PD1/PD-L1-directed therapy.
    Villaruz LC; Socinski MA
    Clin Pharmacol Ther; 2016 Sep; 100(3):212-4. PubMed ID: 27090296
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors.
    Seifert AM; Zeng S; Zhang JQ; Kim TS; Cohen NA; Beckman MJ; Medina BD; Maltbaek JH; Loo JK; Crawley MH; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
    Clin Cancer Res; 2017 Jan; 23(2):454-465. PubMed ID: 27470968
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy.
    Wang X; Yang X; Zhang C; Wang Y; Cheng T; Duan L; Tong Z; Tan S; Zhang H; Saw PE; Gu Y; Wang J; Zhang Y; Shang L; Liu Y; Jiang S; Yan B; Li R; Yang Y; Yu J; Chen Y; Gao GF; Ye Q; Gao S
    Proc Natl Acad Sci U S A; 2020 Mar; 117(12):6640-6650. PubMed ID: 32161124
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer.
    Gong B; Kiyotani K; Sakata S; Nagano S; Kumehara S; Baba S; Besse B; Yanagitani N; Friboulet L; Nishio M; Takeuchi K; Kawamoto H; Fujita N; Katayama R
    J Exp Med; 2019 Apr; 216(4):982-1000. PubMed ID: 30872362
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bu Fei Decoction attenuates the tumor associated macrophage stimulated proliferation, migration, invasion and immunosuppression of non-small cell lung cancer, partially via IL-10 and PD-L1 regulation.
    Pang L; Han S; Jiao Y; Jiang S; He X; Li P
    Int J Oncol; 2017 Jul; 51(1):25-38. PubMed ID: 28534943
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hsa-LINC02418/mmu-4930573I07Rik regulated by METTL3 dictates anti-PD-L1 immunotherapeutic efficacy via enhancement of Trim21-mediated PD-L1 ubiquitination.
    Sun Z; Mai H; Xue C; Fan Z; Li J; Chen H; Huo N; Kang X; Tang C; Fang L; Zhao H; Han Y; Sun C; Peng H; Du Y; Yang J; Du N; Xu X
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040417
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival.
    Markowitz GJ; Havel LS; Crowley MJ; Ban Y; Lee SB; Thalappillil JS; Narula N; Bhinder B; Elemento O; Wong ST; Gao D; Altorki NK; Mittal V
    JCI Insight; 2018 Jul; 3(13):. PubMed ID: 29997286
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
    Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
    Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer.
    Bocanegra A; Fernandez-Hinojal G; Zuazo-Ibarra M; Arasanz H; Garcia-Granda MJ; Hernandez C; Ibañez M; Hernandez-Marin B; Martinez-Aguillo M; Lecumberri MJ; Fernandez de Lascoiti A; Teijeira L; Morilla I; Vera R; Escors D; Kochan G
    Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30986912
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-PD-L1 treatment enhances antitumor effect of everolimus in a mouse model of renal cell carcinoma.
    Hirayama Y; Gi M; Yamano S; Tachibana H; Okuno T; Tamada S; Nakatani T; Wanibuchi H
    Cancer Sci; 2016 Dec; 107(12):1736-1744. PubMed ID: 27712020
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures.
    Della Corte CM; Barra G; Ciaramella V; Di Liello R; Vicidomini G; Zappavigna S; Luce A; Abate M; Fiorelli A; Caraglia M; Santini M; Martinelli E; Troiani T; Ciardiello F; Morgillo F
    J Exp Clin Cancer Res; 2019 Jun; 38(1):253. PubMed ID: 31196138
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade.
    Lo Russo G; Moro M; Sommariva M; Cancila V; Boeri M; Centonze G; Ferro S; Ganzinelli M; Gasparini P; Huber V; Milione M; Porcu L; Proto C; Pruneri G; Signorelli D; Sangaletti S; Sfondrini L; Storti C; Tassi E; Bardelli A; Marsoni S; Torri V; Tripodo C; Colombo MP; Anichini A; Rivoltini L; Balsari A; Sozzi G; Garassino MC
    Clin Cancer Res; 2019 Feb; 25(3):989-999. PubMed ID: 30206165
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Progress in Clinical Researches of PD-1/PD-L1 Checkpoint Inhibitor for Non-small Cell Lung Cancer].
    Wu S; Hu C; Wu F; Wu Y; Liu P
    Zhongguo Fei Ai Za Zhi; 2019 Jul; 22(7):440-448. PubMed ID: 31315783
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.